Switching from intravenous to subcutaneous infliximab – Full Text
"We assessed clinical outcomes over 6 months in an integrated analysis of inflammatory bowel disease (IBD) patients switching from intravenous (IV) to subcutaneous (SC) infliximab (IFX)" Cummings et al (2025).